Occam recently recruited David Mullarkey to Bluestar Genomics. He takes the helm of this rapidly evolving and highly innovative cancer detection company based on the scientific research of Stephen Quake of Stanford University. Dave comes to the role after having had great success as CEO of Omniome which was acquired by Pacific Biosciences and as President and COO of Ariosa Diagnostics sold to Roche. In addition to bringing deep content knowledge to Bluestar, he will provide strategic wisdom and operational discipline to the company’s imminent product launch and commercialization.